ArticlesOnce daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial
Introduction
Integrase inhibitors are a new class of antiretroviral drugs that block the action of HIV integrase, which catalyses several key steps in the life cycle of the virus and is essential for insertion of the viral genome into the DNA of the host cell. Because integration is a vital step in retroviral replication, integrase is a natural target for the treatment.1 The first integrase inhibitor to receive market approval, raltegravir, is effective with good tolerability in combination therapy for HIV in both treatment-naive patients and those who have previously received antiretroviral treatment.2, 3 However, raltegravir must be given twice daily.4, 5 Elvitegravir, another integrase inhibitor in development, is given once daily but needs to be given with a pharmacokinetic booster such as ritonavir or cobicistat.6 Dolutegravir (S/GSK1349572) is a new drug in this class; in cell-culture assays at low nanomolar concentrations it is an effective inhibitor of HIV integrase and HIV replication.7 Pharmacokinetic studies in people have shown a long plasma half-life (about 14 h) without the need for a booster; in short-term monotherapy studies in adults with HIV, change from baseline in HIV RNA viral load ranged from 1·5 log10 copies per mL to 2·5 log10 copies per mL with 2 mg, 10 mg, and 50 mg of dolutegravir once daily.8, 9 Data from in-vitro passage experiments showed the potential for a higher barrier to resistance compared with raltegravir and elvitegravir.7 Finally, in-vitro experiments and data from the ongoing VIKING study (registered with ClinicalTrials.gov, number NCT00950859) suggest that dolutegravir retains activity against viral strains harbouring major integrase-inhibitor resistance mutations selected for by both raltegravir and elvitegravir, including Glu92Gln, Gln148His/Lys/Arg, Asn155His, and Gly140Ser/Gln148His.7, 10, 11, 12, 13 Therefore, dolutegravir has low cross-resistance with the potential for a higher barrier to resistance than other integrase inhibitors.
The objective of our phase 2b study was to assess the efficacy, safety, and pharmacokinetics of three doses of dolutegravir and a standard-care efavirenz-based regimen in adults not previously treated with antiretroviral drugs to select a dose for phase 3 development. Long-term follow-up of these participants will further characterise the risk to benefit ratio of the compound, including assessment of the emergence of drug-resistance isolates in the clinic.
Section snippets
Participants
On July 9, 2009, we started a 96 week, randomised, dose-ranging study in adults infected with HIV who had not previously received treatment, at 34 sites in France, Germany, Italy, Russia, Spain, and the USA. Eligible participants were seropositive for HIV-1, aged 18 years or older, and had a plasma HIV RNA viral load of 1000 copies per mL or greater, and a CD4 count of 200 cells per μL or greater at screening. We excluded any patients that had received more than 10 days of previous treatment
Results
205 individuals were given at least one dose of study drug and comprise both the ITT-E and the safety populations (figure 1). Baseline characteristics were balanced across the study groups with the exception that a larger proportion of patients had baseline HIV RNA greater than 100 000 copies per mL, in the dolutegravir 50 mg once daily group than in the others (table 1). More participants were started on tenofovir plus emtricitabine than abacavir plus lamivudine as the dual-NRTI backbone. Of
Discussion
Dolutegravir has antiviral activity in combination with dual NRTIs in treatment-naive adults with HIV-1. All dolutegravir doses led to similarly high proportions (≥88%) of participants with plasma HIV RNA concentrations of less than 50 copies per mL by week 16, which were maintained to week 48.
The rate of viral decay was much faster in the dolutegravir groups than in the efavirenz group, and was similar to that reported for raltegravir.2, 15 The rapid antiviral response might relate to the
References (22)
- et al.
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial
Lancet
(2007) - et al.
Integrase inhibitors to treat HIV/AIDS
Nat Rev Drug Discov
(2005) - et al.
Raltegravir versus efavirenz regimens in treatment-naive HIV-1 infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses
J Acquir Immune Defic Syndr
(2010) - et al.
Raltegravir with optimized background therapy for resistant HIV-1 infection
N Engl J Med
(2008) Merck reports initial results of phase III study of ISENTRESS® (raltegravir) investigational once-daily dosing in treatment-naïve adult patients infected with HIV-1
- Eron J, Rockstroh J, Reynes J, et al. QDMRK, a phase III study of the safety and efficacy of once-daily vs twice daily...
Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection
Curr Opin Investig Drugs
(2009)- et al.
In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor
Antimicrob Agents Chemother
(2011) - et al.
Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers
Antimicrob Agents Chemother
(2010) - et al.
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults
AIDS
(2011)